RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. Inactive Instrument
Rapid Therapeutic Science Laboratories, Inc. Stock Other OTC
Equities
RTSL
US7534311052
Pharmaceuticals
Financials (USD)
| Sales 2021 | 0 | Sales 2022 | - | Capitalization | 5.82M |
|---|---|---|---|---|---|
| Net income 2021 | -2M | Net income 2022 | -1M | EV / Sales 2021 | 93,978,853,933 x |
| Net Debt 2021 | 1.79M | Net Debt 2022 | 3.83M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-16.6
x | P/E ratio 2022 |
-3.24
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 75.41% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Donal Schmidt
CEO | Chief Executive Officer | 63 | 19-11-14 |
D. Watler
DFI | Director of Finance/CFO | 75 | 19-11-14 |
Sean P. Berrier
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
D. Watler
DFI | Director of Finance/CFO | 75 | 19-11-14 |
Donal Schmidt
CEO | Chief Executive Officer | 63 | 19-11-14 |
Rapid Therapeutic Science Laboratories, Inc. is a biopharmaceutical company. The Company is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company has developed a method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formula of one or more patent pending pharmaceutical-grade cannabinoid compounds. It has developed and is continuing to develop a series of complementary products in addition to its inhaler. It is also focusing on manufacturing its own branded MDI under the nhaler brand name.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +40.86% | 6.16B | |
| -16.30% | 4.49B | |
| -9.93% | 3.17B | |
| -1.58% | 3.01B | |
| -1.70% | 2.57B | |
| +37.23% | 1.8B | |
| -12.78% | 1.62B | |
| +1.02% | 1.56B | |
| -12.97% | 1.53B |
